High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)
National Institutes of Health
At a glance
This funding opportunity is offered by National Institutes of Health. Awards are up to $500,000.
Classification and identifiers
- Solicitation number
- RFA-OD-26-006
- Assistance listing (CFDA)
- 93.077
Amount
$500,000
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). Non-domestic (non-U.S.) components of U.S. OrganizationsForeign components, as defined in the NIH Grants Policy Statement…
About this opportunity
The Tobacco Regulatory Science Program, participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration (FDA) Center for Tobacco Products (CTP) intend to issue a Notice of Funding Opportunity (NOFO) soliciting applications for High-Priority Research Projects in Tobacco Regulatory Science (Clinical Trial Optional). The FDA and NIH share an interest in supporting research that could inform FDA's tobacco regulatory authorities. High-priority research encouraged by this NOFO is expected to provide additional scientific data to the research base to inform the regulation of tobacco products to protect public health. Although a vast and sound science base exists related to the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31, the NOF...
Related opportunities
- Data Standards for Tobacco Research and Scientific Review Phase 2Food and Drug Administration
- Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)National Institutes of HealthCloses in 8 daysUp to $75K
- Research Program Award (R35 Clinical Trial Optional)National Institutes of HealthUp to $750K
- NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)National Institutes of HealthCloses May 2029
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)National Institutes of HealthCloses Nov 2026Up to $150K
- Ancillary Studies to Ongoing Clinical Projects (RP1 Clinical Trial Not Allowed)National Institutes of Health